CBD’s future: Formulas tailor-made to address specific maladies
INTERVIEW: Scott Reese, CEO at US-based C-Beyond Health, says patient-doctor dialog is critical to successful treatment with CBD. HempToday: You describe C-Beyond Health as being…
Medical
U.S. firms join to develop line of medicinal CBD products
Two Colorado, USA companies say they will jointly develop a premium line of medicinal CBD-based products. C-Beyond-Health, based in Golden, and Denver-based Next Frontier Biosciences…
Japanese officials approve Epidiolex for clinical trials
Japanese officials have a approved the medical CBD brand Epidiolex for clinical trials, marking the first time such products have been approved by the Japanese…
WHO committee delays review on global status of cannabis
A World Health Organization (WHO) Committee has delayed until January its review of the global legal status of cannabis, which was expected to be delivered…
Ex-doctor found innocent in Australian cannabis treatment case
An ex-doctor in Australia has sucessfully defended himself in a landmark medical cannabis trial, arguing that his unauthorized treatments with cannabis compounds were of “medical…
Global cannabis stakeholders will descend on Vienna in December
Cannabis, activists, scientists, practitioners and other stakeholders will make presentations at the International Cannabis Policy Conference Dec. 7-9 in Vienna. Some 20 speakers representing 11…
Elixinol debuts on U.S. exchange as Farm Bill vote looms
Denver, Colorado-based Elixinol Global Limited today debuted on the OTCQX Best Market in the USA just ahead of anticipated changes in federal legislation that could…
HT Podcast: Inside the HemPoland sale and what’s ahead for CBD?
Pilot Edition PART ONE: Jacek Kramarz, Sales Director at HemPoland, talks about the evolution of the company before it was acquired in August 2018 by…
Euro CBD market will grow; look for some shakeout globally
Despite significant institutional challenges, the European CBD market will see strong growth for those companies that can navigate the murky waters of EU regulation while…
GW Pharma releases pricing on newly approved CBD-drug
Insured patients in the USA would pay up to $200 per month for CBD-based drug Epidiolex under a recent pricing announcement from the maker, UK-based…